Replimune Group Target Price

See Replimune Group's analyst price targets ($16) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$12.06

Average Target Price

$15.50

28.5% upside

6 analysts in the last 4 months

High: $20 | Low: $9

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-07	BMO Capital	$20	65.8% upside
2026-08-07	WedbushRobert Driscoll	$19	57.5% upside
2026-08-04	Leerink PartnersDaina Graybosch	$17	41% upside
2026-07-31	WedbushRobert Driscoll	$12	0.5% downside
2026-06-30	Wedbush	$9	25.4% downside
2026-06-30	BMO CapitalEvan Seigerman	$16	32.7% upside
2026-02-05	Piper Sandler	$14	16.1% upside
2025-11-03	BMO CapitalEvan Seigerman	$11	8.8% downside
2025-10-27	H.C. Wainwright	$12	0.5% downside
2025-10-20	Wedbush	$18	49.3% upside
2025-01-22	BMO CapitalEvan Seigerman	$27	123.9% upside
2024-12-03	JefferiesRoger Song	$19	57.5% upside
2024-06-07	H.C. WainwrightRobert Burns	$17	41% upside
2024-06-04	BarclaysPeter Lawson	$13	7.8% upside
2024-05-17	BMO CapitalEvan Seigerman	$14	16.1% upside
2022-12-12	BMO Capital	$70	480.4% upside
2022-12-07	Leerink Partners	$34	181.9% upside
2022-10-03	Leerink Partners	$30	148.8% upside
2022-08-17	Piper Sandler	$43	256.6% upside
2022-08-05	Leerink Partners	$37	206.8% upside
2022-05-20	Leerink Partners	$48	298% upside

Replimune Group (REPL) FAQ

Replimune Group posts a target price of $16. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $16 for REPL means covering analysts, on average, see the stock 28.5% upside of $12.06 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for REPL's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Replimune Group's other metric pages and overview cover the third.

Judging Replimune Group against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $16 here, then scan peer and history charts to see if the gap is persistent.